Logo

Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021

Share this
Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021

Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021

Shots:

  • The RAINBOWFISH study evaluates the efficacy and safety of Evrysdi in babies aged birth to 6wks. with pre-symptomatic SMA
  • The results showed that 4 out of 5 patients treated with Evrysdi for 12 mos. were able to stand & walk independently within the WHO windows for healthy children. Additionally- all five infants maintained the ability to swallow and were able to feed exclusively orally after 12mos. of treatment
  • The results further support the continued clinical investigation of SRP-9001 in DMD. Additionally- the company also presents the data from the SRP-9001- 101/002/003 studies evaluating the efficacy- safety- and durability of SRP-9001 for DMD

  Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions